Cannabis, CBD, Hemp Oil -New Found Treatment For Cancer, Drug and Alcohol Addictions

Hemp Hearts

hemp hearts

1Cannabis sativa flower coated with trichomes bearing cannabodiol and other cannabinoids


Thousands of people have healed their own body of cancer after the conventional doctors gave up on them. Thousands of people has cured their own body of drug and alcohol addictions – The substance they used? HEMP OIL… CBD. CANNABIS- LEGAL IN ALL 50 STATES!

Best by: 7/31/

I have ‘egg on my face’ because I was one of those people, 100% against “pot”, “weed”, “marijuana”, “cannabis”, “hashish”, or anything resembling or smelling like it. Everything I knew about the substance was not based on true research or history of this plant. It was based on what the “hippies” used it for and it was not for medical reasons!

After researching for about a year on this substance, I have realized what a powerful healing plant hemp is.

This past year there has been a large interest in cannabidiol (CBD) among doctors and scientists and patients concerned about its therapeutic values. It has been proven to shrink tumors, stop seizures and ease chronic pain, without intoxicating the patient and causing them to feel “stoned” as the “hippies” would say.

There has been a lot of confusion about hemp extracts, CBD and THC.


CBD Biology and Therapeutic Rationale

CBD is one of more than 80 active cannabinoid chemicals in the marijuana plant. Unlike the main psychoactive cannabinoid in marijuana, tetrahydrocannabinol (THC), CBD does not produce euphoria or intoxication. Cannabinoids have their effect mainly by interacting with specific receptors on cells in the brain and body: the CB1 receptor, found on neurons and glial cells in various parts of the brain, and the CB2 receptor, found mainly in the body’s immune system. The euphoric effects of THC are caused by its activation of CB1 receptors. CBD has a very low affinity for these receptors (100 fold less than THC) and when it binds it produces little to no effect. There is also growing evidence that CBD acts on other brain signaling systems, and that these actions may be important contributors to its therapeutic effects.

Clinical Evidence:

Clinical research (including both cell culture and animal models) has shown CBD to have a range of effects that may be therapeutically useful, including anti-seizure, antioxidant, neuroprotective, anti-inflammatory, analgesic, anti-tumor, anti-psychotic, and anti-anxiety properties.

Anti-Seizure Effects:

The Wall Street Journal
Studies are under way to test the effectiveness of a marijuana extract that has been hailed as a wonder drug by some parents whose children suffer severe forms of epilepsy. But as initial findings from several researchers trickle in, the results are proving mixed.

A dozen states in the past year, including Florida and Kentucky, have legalized the substance—cannabidiol, or CBDdespite a lack of hard evidence of its effectiveness in controlling seizures. Another nine states are weighing CBD legislation. Some of the bills have been named after children in those states with severe epilepsy and whose families were desperate for an alternative after trying other medications that failed.

Democratic Sens. Cory Booker and Kirsten Gillibrand, as well as Republican Sen. Rand Paul, unveiled arguably the most progressive medical marijuana legislation is history on Tuesday.

Their new bill — The Compassionate Access, Research Expansion and Respect States (CARERS) Act — would end federal prohibition of medical marijuana and also introduce a host of other reforms aiming to curb restrictions on its transport, prescription and availability.

“We need policies that empower states to legalize medical marijuana if they so choose — recognizing that there are Americans who can realize real medical benefits if this treatment option is brought out of the shadows,” Booker told reporters at a press conference Tuesday on Capitol Hill. “Doctors and patients deserve federal laws that are fair and compassionate, and states should be able to set their own medical marijuana policies without federal interference.”

“Otherwise law-abiding Americans — bankers, business people, veterans, families — are fearful of unnecessary, expensive, life-disrupting investigations and prosecutions,” he added. “Today we join together to say enough is enough.”

The legislation has drawn praise from drug policy reform advocates. “It’s the most comprehensive medical marijuana bill in Congress,” Bill Piper, director of national affairs for the Drug Policy Alliance, told the Washington Post on Monday.

“It really is a comprehensive bill — it would effectively end the federal war on medical marijuana,” added Tom Angell, chairman of the advocacy group Marijuana Majority, in the same report.

“Current federal law turns its back on families in need of this medicine, which doctors want to prescribe to ease pain and suffering,” Gillibrand said on Tuesday. “Senators Booker, Paul and I agree that it’s time to modernize our laws and recognize the health benefits of medical marijuana. The CARERS Act will no longer put politicians between doctors and patients…”


Below is an opinion letter written from a top-notch attorney regarding the legalities of CBD derived from the hemp plant. His final verdict is that CBD from hemp breaks no state, national or federal laws and is legal in all 50 states.

An important term for anyone interested in starting a CBD hemp oil supplement routine to know is cannabinoid. It is cannabinoids that provide users with the benefits of cannabis.

Cannabinoids are a class of active chemical compounds produced by the cannabis plant. These cannabinoids act on cannabinoid receptors located in our cells as part of the endocannabinoid system and alter the release of neurotransmitters in the brain.

There are over 100 presently discovered cannabinoids, which are largely responsible for the effects cannabis has on the body. Common cannabinoids include tetrahydrocannabinol or THC, cannabidiol or CBD, cannabinol or CBN, and cannabigerol or CBG.

Though cannabinoids are present in the cannabis plant naturally as their carboxylic acid forms, these cannabinoids are converted to their active forms when they undergo a process called decarboxylation, where heat, light, or alkaline conditions cause the cannabinoids to lose their carboxyl group.


Cannabinoids can be found in three places: formed by plants, produced naturally by the human body, and created artificially in a lab.  

Endocannabinoids – like Anandamide and 2-AG – are naturally occurring cannabinoids made by the human body. Anandamide, named for the sanskrit word for bliss, is similar in its construction and effects to THC. On the other hand, 2-arachidonoylglycerol or 2-AG is analogous to CBD.

Phytocannabinoids come from plants. When users consume cannabis, the cannabinoids in the marijuana plant are absorbed by the body. However, cannabinoid-like chemical compounds that interact with the body’s endocannabinoid system are also found in echinacea, black pepper, and even cacao.

It is also possible to create synthetic cannabinoids in a lab. These synthetic cannabinoids mimic the effects of natural cannabinoids and can be utilized alongside phytocannabinoids to develop novel new pharmaceutical treatments.

Cannabinoids can be administered using several methods, including smoking, vaporization, oral ingestion, sublingual absorption, or even by transdermal patch.

Regardless of their source, when consumed, cannabinoids interact with the body’s endocannabinoid system where they bind with the CB1 and CB2 cannabinoid receptors. Here, cannabinoids stimulate the endocannabinoid system, triggering cannabis’s beneficial effects and promoting homeostasis and systemic balance.

Neuroprotective and anti-inflammatory Effects:

CBD has also been shown to have neuroprotective properties in cell cultures as well as in animal models of several neurodegenerative diseases, including Alzheimer’s, stroke, glutamate toxicity, multiple sclerosis (MS), Parkinson’s disease, and neurodegeneration caused by alcohol abuse. Nabiximols (trade name Sativex), which contains THC and CBD in roughly equal proportions, has been approved throughout most of Europe and in a number of other countries for the treatment of spasticity associated with MS. It has not been approved in the United States, but clinical trials are ongoing, and two recent studies reported that nabiximols reduced the severity of spasticity in MS patients.

Analgesic Effects:

When a doctor is face-to-face with a chronic pain patient who says, “My pain is worse, the opioids aren’t working, I need more. If I don’t get them I’m not going to be able to go to work, I’m not going to be able to support my family, I’m not going to be able to function”—it’s hard for that clinician to say no, because they don’t have another tool.

Adding cannabis to opioids makes the opioids safer. Cannabis can prevent opioid tolerance building and the need for dose escalation. Cannabis can treat the symptoms of opioid withdrawal. And cannabis is safer than other harm reduction options for people that are addicted or dependent on opioids.

Anti-Anxiety Effects:

CBD has shown therapeutic efficacy in a range of animal models of anxiety and stress, reducing both behavioral and physiological (e.g., heart rate) measures of stress and anxiety. In addition, CBD has shown efficacy in small human laboratory and clinical trials. CBD reduced anxiety in patients with social anxiety subjected to a stressful public speaking task. In a laboratory protocol designed to model post-traumatic stress disorders, CBD improved “consolidation of extinction learning”, in other words, forgetting of traumatic memories. The anxiety-reducing effects of CBD appear to be mediated by alterations in serotonin receptor 1a signaling, although the precise mechanism remains to be elucidated and more research is needed.

Safety of CBD:

Despite its molecular similarity to THC, CBD only interacts with cannabinoid receptors weakly at very high doses (100 times that of THC), and the alterations in thinking and perception caused by THC are not observed with CBD. The different pharmacological properties of CBD give it a different safety profile from THC.

One of the biggest problems with long-term opioid treatment is that it stops working. People build up tolerance to opioids, they come back every three to six months saying, ‘I want more, I need more.’

So what about cannabis? First of all, cannabis has a much better safety profile than Methadone or Suboxone. There’s no lethal overdose with cannabis. You can have a fatal overdose on Methadone; the same for Suboxone, especially if you’re taking it with a Benzo (like Valium or Clonazepam) or another agent that suppresses cardiorespiratory function. Yet these drugs are often prescribed together.

Cannabis, by comparison, has a lower risk of dependence than any other psychoactive substance. It also has a low risk for abuse and diversion, especially in nonsmokable forms. There’s currently over 30,000 patient years of data, mostly in randomized control trials using a cannabis extract, a sublingual spray called Nabiximols, usually tested for the treatment of pain and spasticity. It’s already approved in 27 countries. In that huge data set, there’s been no evidence of abuse or diversion. That’s really impressive. What’s more, most people who stop using cannabis are able to do so without any formal treatment.

Passing a state medical cannabis law on average reduced opioid overdose deaths by 24.8 percentJournal of the American Medical Association.

What are our current harm reduction options for treating opioids? Two main harm reduction approaches for opioids are accepted in mainstream medicine right now. One is Buprenorphine which, when combined with an opioid blocking drug called Naloxone, is sold as Suboxone. And we also have Methadone, although it’s debatable whether Methadone is safer than heroin. A 2014 review in the Cochrane Database assessed the efficacy of these approved heroin substitution options and found that only high-dose Buprenorphine was more effective than placebo in suppressing illicit opioid use. Low dose and medium dose Buprenorphine in trials did not suppress the opioids better than placebo. Methadone maintenance was found to be superior to Buprenorphine in retaining people in treatment.

We need something more. So what about cannabis? First of all, cannabis has a much better safety profile than Methadone or Suboxone. There’s no lethal overdose with cannabis. You can have a fatal overdose on Methadone; the same for Suboxone, especially if you’re taking it with a Benzo (like Valium or Clonazepam) or another agent that suppresses cardiorespiratory function. Yet these drugs are often prescribed together.

Cannabis, by comparison, has a lower risk of dependence than any other psychoactive substance. It also has a low risk for abuse and diversion, especially in nonsmokable forms. There’s currently over 30,000 patient years of data, mostly in randomized control trials using a cannabis extract, a sublingual spray called Nabiximols, usually tested for the treatment of pain and spasticity. It’s already approved in 27 countries. In that huge data set, there’s been no evidence of abuse or diversion. That’s really impressive. What’s more, most people who stop using cannabis are able to do so without any formal treatment.

Cannabis does something to help patients stay in recovery, to stay out of that addictive chapter of their life and to move on to something new. There’s evidence elsewhere in the scientific literature that suggests cannabinoids can promote neuroplastic changes in the brain, changes literally in the structure of the brain related to new behavior, new thought patterns. That’s exactly what we need to get someone out of that addictive cycle into a new phase of life.

People often ask, what about the gateway theory? What about getting addicted to cannabis? Aren’t we just replacing one addiction with another? Well, we’ve already discussed harm reduction, but let’s look at how addictive cannabis actually is. According to the National Institute of Drug Abuse, lifetime risk for dependence on cannabis is 9 percent. That’s less than alcohol, opiates or any other drugs of abuse. But that 9 percent figure is exaggerated; it includes people who were in court-mandated treatment programs. Quite a few people who get busted for cannabis are not addicted to it; they’re using it recreationally, or even medically, and because of their legal issues they end up in drug treatment. That skews the numbers.

Medical cannabis should be a first-line treatment for opioid addiction, not a last resort.

Indeed, abruptly ceasing chronic cannabis use can cause withdrawal symptoms. People can become dependent on it. Cannabis withdrawal symptoms include irritability, nervousness, anxiety, anger or aggression, decreased appetite, weight loss, restlessness, sleep difficulty, strange dreams. Symptoms appear one to two days after stopping chronic cannabis use and last at most two weeks. But our patients consistently report that cannabis withdrawal is relatively mild, very similar to caffeine withdrawal.

A 2015 study from the journal of American Medical Association, looked at the data of actual medical cannabis instead of illicit cannabis. Indeed, medical cannabis can have unwanted side effects. But these side effects were typically quite mild and they can be mediated by dosage. So when you use programs like or when you have a cannabis clinician who knows what they’re doing, they can walk you through how to use cannabis and get the right dosage. It’s possible to use cannabis without any side effects at all. Many of our patients do that.

During the decades of prohibition, cannabis breeders grew strains that had more and more THC [The High Causer] and less and less of the sister cannabinoids because that’s what sells on the black market. People want to buy something that’s pleasantly intoxicating. But recently there’s been a shift, a complete reversal, where people who are medical patients want serious symptom relief, they want the medical benefits, but many people don’t want to get high or impaired.

Significant medical benefits are attributed to a non-intoxicating sister molecule of THC called CBD or cannabidiol. CBD has been shown to reduce the side effects caused by THC and to enhance the benefits of THC. In some animal studies, CBD has been shown to decrease addictive behavior; medical scientists found that the heroin-seeking behavior of self-administering rats decreased when the animals were given CBD.

While CBD is generating a lot of excitement and hope within the medical community, concerns persist about how medical cannabis laws might impact young people. If we pass medical cannabis or adult-use legalization, aren’t more adolescents going to start smoking marijuana? If they perceive cannabis as safe, aren’t they’re going to get into it at a younger age?

Several studies have addressed this question with encouraging results. A 2015 study in the Lancet Psychiatry journall found, “There is no evidence of a differential increase in past month use in youths that can be attributed to state medical marijuana laws.” And a 2016 study in The International Journal of Drug Policy that found “no evidence for an increase in adolescent marijuana use after the passage of state laws permitting use of marijuana for medical purposes. Concerns that increased marijuana use is an unintended effect of state marijuana laws seem unfounded.”


In summary, the opioid problem is lethal and growing. Prescription opioid abuse is actually worse than heroin abuse; it’s a bigger problem, and it starts in the doctor’s office. Cannabis can replace and reduce opioid use. Adding cannabis makes opioids safer by widening the therapeutic index. Cannabis can prevent opioid tolerance-building and the need for dose escalation. And cannabis can treat the symptoms of opioid withdrawal. Finally, cannabis is safer than the other harm reduction options.

FACTS About Cannabis and Opiate Addiction

    • Forty-four people die every day from prescription opioid overdose in America. Almost 7,000 people are treated in emergency rooms in the United States every day for misuse of a prescription opioid.
    • States with medical cannabis laws on average reduced opioid overdose deaths by 24.8 percent. And each year after the medical cannabis law was passed, the rate of opioid overdose deaths continued to decrease, according to a report in the Journal of the American Medical Association.
    • Prescription opioid abuse is actually worse than heroin abuse. In 2014, there were around 19,000 overdose deaths from opioid prescriptions and around 11,000 overdose deaths from heroin. Nearly 80 percent of heroin users in the United States reported using prescription opioids before initiating heroin use.
    • Extensive scientific, randomized controlled trials have shown that a cannabis oil extract can be an effective treatment for chronic neuropathic pain.
    • Cannabis improves the pain relief that opioids provide. Medical scientists have found that administering opioids and cannabis together results in a greater-than-additive anti-pain effect, a synergistic reduction of pain.
    • Cannabis makes opioid therapy safer by widening the therapeutic index so that a patient needs less opioids to get a strong analgesic effect.
    • Cannabis can prevent opioid tolerance building and the need for dose escalation.
    • Cannabis can treat the symptoms of opioid withdrawal—nausea, vomiting, spasms, cramping, insomnia. Cannabis users experience decreased opioid withdrawal severity.
    • Cannabis can replace and reduce the use of opioids and other substances. Many patients use cannabis as a substitute for prescription drugs, illicit drugs, or alcohol.
    • Cannabis therapy is safer than the other harm reduction options.

    We follow all US government guidelines in our practices

     First, it is important to understand that we are not doctors and cannot give out medical advice, nor can we address specific medical concerns directly. In fact, HIPPA has strict standards for this kind of advice distributed via email, and or phone consultations, and the FDA also has strict standards regulating what can and cannot be said about any substance ingested for health purposes… and we strictly adhere to all US government guidelines and regulations in our practices.

    We are however able to discuss what has been learned about Cannabinoids, and also help focus your inquiries so as to help address your health concerns.  In addition, we fully respect the medical community and believe that a mix of influences is always helpful when individuals are seeking health advice as this is such an important and personal matter… So, please use the resources on our site and also available online to understand the science of CBD.


    Sources :

National Institute of Health

Dr.Dustin Sulak of Integr8 Health.

Abrams D, et al, “Cannabinoid-opioid interaction in chronic pain,” Clin Pharmacol Ther, Epub 2011 Nov 2.

Bachhuber, Marcus A, et al, “Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010,” JAMA Intern Med, 2014 Oct.

Boehnke KF, et al, “Medical Cannabis Use is Associated With Decreased Opiate Medication in a Retrospective Cross-Sectional Survey of Patients with Chronic Pain,” J Pain, 2016 Jun.

Chou, Roger, et al, “The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop,” Annals of Internal Medicine, 17 February 2015.

Haroutounian S, et al, “The Effect of Medicinal Cannabis on Pain and Quality of Life Outcomes in Chronic Pain: A Prospective Open-label Study,” Clin J Pain, 2016 Feb 17.

Hasin, Deborah S, et al, “Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: results from annual, repeated, cross-sectional surveys,” The LANCET Psychiatry, July 2015.

Koppel BS, et al, “Systematic review: efficacy and safety of medical marijuana in selected neurological disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology,” Neurology, 2014 April 29.

Lucas, Philippe, et al, “Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors,” Drug and Alcohol Review, 14 Sept 2015.

Mattick RP, et al, “Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence,” Cochrane Database Syst Rev, 2014 Feb 6.

Raby WN, et al, “Intermittent marijuana use is associated with improved treatment retention in naltrexone treatment for opiate-dependence,” Am J Addict, 2009 Jul-Aug.

Wall MM, et al, “Prevalence of marijuana use does not differentially increase among youth after states pass medical marijuana laws: Commentary on and reanalysis of US National Survey on Drug Use in Households data 2002-2011,” Intl J Drug Policy, 2016 Mar.

Whiting PF, et al, “Cannabinoids for Medical Use: A Systematic Review and Meta-analysis,” JAMA, 20